Latest news with #CheckpointTherapeutics
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
5 days ago
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
Associated Press
7 days ago
- Business
- Associated Press
Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, 'Sun Pharma')) today announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. ('Checkpoint'), an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYT™, the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. 'This acquisition exemplifies Sun Pharma's commitment to supporting patients and growing its innovative therapies business,' said Dilip Shanghvi, Chairman & Managing Director of Sun Pharma. 'By adding UNLOXCYT™, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio.' Financial Terms Sun Pharma has acquired all outstanding shares of Checkpoint at a price of $4.10 per share in cash, without interest, plus one non-tradable contingent value right (CVR) per share representing the right to receive up to an additional $0.70 in cash, without interest, if certain specified milestones are met, as set out in the terms and conditions of the contingent value rights agreement. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). About Cutaneous Squamous Cell Carcinoma Cutaneous squamous cell carcinoma ('cSCC') is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. Important risk factors for cSCC include chronic ultraviolet exposure and immunosuppressive conditions. While most cases are localized tumors amenable to curative resection, each year approximately 40,000 cases become advanced and an estimated 15,000 people in the United States die from this disease. In addition to being a life-threatening disease, cSCC causes significant functional morbidities and cosmetic deformities due to tumors that commonly arise in the head and neck region, and that invade blood vessels, nerves and vital organs, such as the eye or ear. UNLOXCYT™ INDICATION and IMPORANT SAFETY INFORMATION INDICATION UNLOXCYT™ (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. IMPORTANT SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions Immune-Mediated Pneumonitis Immune-Mediated Colitis Immune-Mediated Hepatitis Immune-Mediated Endocrinopathies Adrenal Insufficiency Hypophysitis Thyroid Disorders Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis Immune-Mediated Nephritis with Renal Dysfunction Immune-Mediated Dermatologic Adverse Reactions Other Immune-Mediated Adverse Reactions Infusion-Related Reactions Complications of Allogeneic HSCT Embryo-Fetal Toxicity Common Adverse Reactions The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection. Please see full Prescribing Information. Sun Pharma Contacts: Investors Dr. Abhishek Sharma +91 22 4324 2929 [email protected] Media (Global) Gaurav Chugh +91 22 4324 5373 [email protected] Media (USA) James Freeman +1 978-808-6956 [email protected] View original content to download multimedia: SOURCE Sun Pharma
Associated Press
10-03-2025
- Business
- Associated Press
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone is fair to Checkpoint shareholders. Halper Sadeh encourages Checkpoint shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Checkpoint and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Checkpoint shareholders; (2) determine whether Sun Pharmaceutical is underpaying for Checkpoint; and (3) disclose all material information necessary for Checkpoint shareholders to adequately assess and value the merger consideration. On behalf of Checkpoint shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. CONTACT: Halper Sadeh LLC One World Trade Center 85th Floor New York, NY 10007 Daniel Sadeh, Esq. Zachary Halper, Esq. SOURCE: Halper Sadeh LLC Copyright Business Wire 2025. PUB: 03/10/2025 08:05 AM/DISC: 03/10/2025 08:07 AM
Reuters
10-03-2025
- Business
- Reuters
India's Sun Pharma to acquire Checkpoint Therapeutics
March 10 (Reuters) - India's Sun Pharmaceutical Industries ( opens new tab said on Monday that it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 million.
